These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37289449)

  • 1. Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015.
    Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
    JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy.
    Xiang M; Chang DT; Pollom EL
    Cancer; 2020 Aug; 126(15):3560-3568. PubMed ID: 32426866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.
    Sheets NC; Goldin GH; Meyer AM; Wu Y; Chang Y; Stürmer T; Holmes JA; Reeve BB; Godley PA; Carpenter WR; Chen RC
    JAMA; 2012 Apr; 307(15):1611-20. PubMed ID: 22511689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer.
    Bekelman JE; Mitra N; Efstathiou J; Liao K; Sunderland R; Yeboa DN; Armstrong K
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e325-34. PubMed ID: 21498008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
    Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.
    Sveistrup J; af Rosenschöld PM; Deasy JO; Oh JH; Pommer T; Petersen PM; Engelholm SA
    Radiat Oncol; 2014 Feb; 9():44. PubMed ID: 24495815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
    Shimizuguchi T; Nihei K; Okano T; Machitori Y; Ito K; Karasawa K
    Int J Clin Oncol; 2017 Apr; 22(2):373-379. PubMed ID: 27778117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.
    Hummel S; Simpson EL; Hemingway P; Stevenson MD; Rees A
    Health Technol Assess; 2010 Oct; 14(47):1-108, iii-iv. PubMed ID: 21029717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer.
    Lin SH; Zhang N; Godby J; Wang J; Marsh GD; Liao Z; Komaki R; Ho L; Hofstetter WL; Swisher SG; Mehran RJ; Buchholz TA; Elting LS; Giordano SH
    Cancer; 2016 Mar; 122(6):917-28. PubMed ID: 26716915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Postoperative Intensity-Modulated Radiation Therapy Use and Its Association With Survival Among Patients With Incompletely Resected Non-Small Cell Lung Cancer.
    Yu B; Jun Ma S; Waldman O; Dunne-Jaffe C; Chatterjee U; Turecki L; Gill J; Yendamuri K; Iovoli A; Farrugia M; Singh AK
    JAMA Netw Open; 2022 Sep; 5(9):e2230704. PubMed ID: 36074462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
    Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
    JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer.
    Pinkawa M; Piroth MD; Holy R; Djukic V; Klotz J; Krenkel B; Eble MJ
    Strahlenther Onkol; 2011 Aug; 187(8):479-84. PubMed ID: 21789739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy.
    Liu BY; Rehmani S; Kale MS; Marshall D; Rosenzweig KE; Kong CY; Wisnivesky J; Sigel K
    Chest; 2022 Jun; 161(6):1666-1674. PubMed ID: 35063448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy.
    Goldin GH; Sheets NC; Meyer AM; Kuo TM; Wu Y; Stürmer T; Godley PA; Carpenter WR; Chen RC
    JAMA Intern Med; 2013 Jun; 173(12):1136-43. PubMed ID: 23689844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
    Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
    Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
    Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
    Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results.
    Shen Q; Ma X; Hu W; Chen L; Huang J; Guo Y
    Radiat Oncol; 2013 Jun; 8():152. PubMed ID: 23800149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers.
    Chen LA; Kim J; Boucher K; Terakedis B; Williams B; Nickman NA; Gaffney DK
    Gynecol Oncol; 2015 Mar; 136(3):521-8. PubMed ID: 25562668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of intensity modulated radiation therapy to 3-dimensional conformal radiation in locally advanced lung cancer: pathological and clinical outcomes.
    Appel S; Bar J; Ben-Nun A; Perelman M; Alezra D; Urban D; Ben-Ayun M; Honig N; Ofek E; Katzman T; Onn A; Chatterji S; Dubinski S; Tsvang L; Felder S; Kraitman J; Haisraely O; Rabin Alezra T; Lieberman S; Marom EM; Golan N; Simansky D; Symon Z; Lawrence YR
    Br J Radiol; 2019 May; 92(1097):20180960. PubMed ID: 30864828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.